Answers are grounded in this paper and cite their sources.
Randomized trial shows that co-administering B. breve PRL2020 significantly alleviates gut symptoms in children treated with antibiotics, indicating a potential therapeutic strategy.
Diarrhea caused by amoxicillin (A) or amoxicillin-clavulanate (AC) is common in children, and the induced dysbiosis is often characterized by a severe reduction in bifidobacteria. However, bifidobacteria are extremely antibiotic-sensitive, and their co-administration with antibiotics is likely unwise. The B. breve PRL2020 strain is an A- and AC-resistant probiotic. In a multicenter, randomized, controlled, non-profit study, we tested the tolerability and efficacy of the PRL2020 strain when co-administered to children (3-12 years; N = 121) undergoing A or AC therapy, attempting to interpret the results obtained by observing the intestinal microbiota in a subgroup (N = 41) of enrolled children. In children treated with the probiotic, the therapy was well tolerated and the incidence of diarrhea was significantly reduced by approximately 70% (p < 0.01). Considering only children with diarrhea, in the probiotic-treated group the onset was postponed by about 15 h, and the symptom lasted 19 h less. Gut microbiota richness was significantly reduced in both groups, without significant differences between probiotic-treated and control children. At the phylum level, antibiotic treatment was associated with an increase in Proteobacteria and a reduction in Actinobacteria, with larger apparent shifts in the control group. Bifidobacteria, particularly B. breve, decreased in controls and increased in treated subjects (p < 0.05), despite not being among the most abundant taxa contributing to the majority of the microbial community. Finally, although only in a trend-based manner, butyrate-producing bacteria decreased less in probiotic-treated children, whereas an increase in succinate-consuming bacteria was observed in controls. Co-administering the B. breve PRL2020 strain with A or AC in children significantly reduces diarrheal symptoms and antibiotic-related dysbiotic status. New blinded, placebo-controlled studies with a more robust sample size for microbiota analysis will have to confirm our data.
No takes yet. Share an insight, caveat, or question.
Pierro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: